Organ Protection With Sevoflurane Postconditioning

This study has been completed.
Information provided by:
University of Zurich Identifier:
First received: August 20, 2007
Last updated: July 18, 2011
Last verified: July 2011
Organ protection, volatile anesthetics, postconditioning, hepatic surgery

Condition Intervention
Drug: Sevoflurane

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Role of Volatile Anesthetics for Hepatic Protection in Ischemia-reperfusion: Postconditioning

Resource links provided by NLM:

Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • Liver transaminase AST [ Time Frame: Postoperative phase until discharge ] [ Designated as safety issue: No ]
    Peak value

Secondary Outcome Measures:
  • ALT peak value [ Time Frame: Postoperative phase until discharge ] [ Designated as safety issue: No ]
  • Course of transaminases [ Time Frame: From the day before surgery, to 6 hours after surgery, up to postoperative day 7 ] [ Designated as safety issue: No ]
  • Postoperative complications [ Time Frame: Postoperative phase until discharge ] [ Designated as safety issue: Yes ]
  • Length of hospital stay [ Time Frame: Postoperative phase until discharge ] [ Designated as safety issue: No ]
  • Need for prolonged intensive care unit stay (>24 hours) [ Time Frame: Postoperative phase until discharge ] [ Designated as safety issue: No ]

Enrollment: 125
Study Start Date: January 2008
Study Completion Date: September 2010
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sevoflurane
Sevoflurane for pharmacological postconditioning
Drug: Sevoflurane
3.2 Vol % for postconditioning
Experimental: Propofol
Anesthesia maintenance with propofol instead of Sevoflurane postconditioning
Drug: Sevoflurane
3.2 Vol % for postconditioning

Detailed Description:
This study aims at the evaluation of a potential attenuation of ischemic-reperfusion injury in the liver with sevoflurane postconditioning upon reperfusion.

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • older than 18 years
  • patients undergoing liver resection (benign or malignant tumors)

Exclusion criteria:

  • non-german speakers
  • laparoscopic liver resection
  • coagulopathy (platelets < 50'000/ml, Quick < 50%)
  • liver cirrhosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00518908

University Hospital of Zurich
Zurich, Switzerland
Sponsors and Collaborators
University of Zurich
Study Director: 01 Studienregister MasterAdmins UniversitaetsSpital Zuerich
  More Information

No publications provided

Responsible Party: BECK SCHIMMER Beatrice, Professor, University Hospital Zurich, Department of Anesthesiology Identifier: NCT00518908     History of Changes
Other Study ID Numbers: StV 34-2007 
Study First Received: August 20, 2007
Last Updated: July 18, 2011
Health Authority: Switzerland: Swissmedic

Keywords provided by University of Zurich:
Ischemia reperfusion injury
Organ protection

Additional relevant MeSH terms:
Anesthetics, General
Anesthetics, Inhalation
Central Nervous System Agents
Central Nervous System Depressants
Hematologic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Therapeutic Uses processed this record on February 11, 2016